Title
Increased CSF <tex>$\alpha$</tex>-synuclein levels in Alzheimer's disease : correlation with tau levels Increased CSF <tex>$\alpha$</tex>-synuclein levels in Alzheimer's disease : correlation with tau levels
Author
Faculty/Department
Faculty of Medicine and Health Sciences
Faculty of Pharmaceutical, Biomedical and Veterinary Sciences . Biomedical Sciences
Publication type
article
Publication
,
Subject
Human medicine
Source (journal)
Alzheimer's & dementia. - Place of publication unknown
Volume/pages
(2014) , p. 1-9
ISSN
1552-5260
Carrier
E
Target language
English (eng)
Full text (Publishers DOI)
Affiliation
University of Antwerp
Abstract
Background Given the difficult clinical differential diagnosis between Alzheimer's disease (AD) and dementia with Lewy bodies (DLB), growing interest resulted in research on α-synuclein as a potential cerebrospinal fluid biomarker (CSF) for synucleinopathies. Methods CSF α-synuclein-140 concentrations were determined by a prototype xMAP bead-based assay (Innogenetics NV, Belgium). In addition, CSF amyloid β1-42 (Aβ1-42), total tau (T-tau), and phosphorylated tau (P-tau181P) levels were determined. Results CSF α-synuclein levels were higher in AD patients as compared with cognitively healthy controls (P = .019) and patients with synucleinopathies (P < .001). CSF α-synuclein levels were correlated with T-tau (P < .001) and P-tau181P (P < .001) levels in autopsy-confirmed AD patients. A diagnostic algorithm using α-synuclein and P-tau181P discriminated neuropathologically confirmed AD from DLB patients, resulting in sensitivity and specificity values of 85% and 81%, respectively. Conclusion Because CSF α-synuclein levels were significantly higher in AD as compared with synucleinopathies, α-synuclein might have a value as a biomarker for differential dementia diagnosis.
E-info
https://repository.uantwerpen.be/docman/iruaauth/817c5c/d8e1f5ab7bc.pdf
Handle